Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J0593 Injection., lanadelumab-flyo, 1 milligrams

J Codes (Drugs)

Also known as: lanadelumab-flyo, Takhzyro

Lanadelumab-flyo injection, 1 milligram, a monoclonal antibody against plasma kallikrein for prophylaxis of hereditary angioedema attacks.

In Plain Language

hereditary swelling prevention injection; angioedema prevention

Clinical Context

First monoclonal antibody approved for hereditary angioedema (HAE) prophylaxis, targeting contact system activation. Administered subcutaneously every 2 or 4 weeks based on patient response.

RVU Information

CPT J0593 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

allergyimmunologyemergency medicine

Frequently Asked Questions

What is CPT code J0593?

CPT J0593 (Injection., lanadelumab-flyo, 1 milligrams) is a J Codes (Drugs) code. Lanadelumab-flyo injection, 1 milligram, a monoclonal antibody against plasma kallikrein for prophylaxis of hereditary angioedema attacks.

How is J0593 administered?

CPT J0593 is administered by a healthcare provider, typically via injection or infusion. First monoclonal antibody approved for hereditary angioedema (HAE) prophylaxis, targeting contact system activation. Administered subcutaneously every 2 or 4 weeks based on patient response. It is used by allergy, immunology, emergency medicine.

When is CPT J0593 used?

First monoclonal antibody approved for hereditary angioedema (HAE) prophylaxis, targeting contact system activation. Administered subcutaneously every 2 or 4 weeks based on patient response.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.